The overall goal of the Cell Therapies Core (CTC) is to provide service to members to facilitate translation of promising therapies for patients with cancer. The CTC manufactures cellular products in support of novel, investigator-initiated clinical studies, while maintaining compliance with standards set by the U.S. Food and Drug Administration (FDA) and other accrediting bodies. To accomplish this goal, the CTC's Specific Aims are to: 1) Develop new technologies for translation of cellular therapies 2) Provide regulatory assistance in support of cellular therapies 3) Educate and train scientists and clinicians committed to careers in cellular therapies 4) Produce the highest quality cellular products for immunotherapy clinical trials The CTC works with members through all stages of a clinical trial, including collaboration during pre-clinical planning. The CTC technical director, manager, and quality staff assist with preparation of protocols, funding/grant applications, INDs, and other regulatory submissions. Once the cellular therapy agent under study is administered to the patient, the CTC analytic laboratory may continue to assist in post-treatment immune monitoring or, when desired by investigators, may directly conduct the immune monitoring studies. The CTC has four key areas of activity: 1. New product development, wherein new cell therapy products undergo pre-clinical scale-up, testing, and validation 2. Cell collection and cryostorage to obtain mononuclear cells, lymphocytes, and antigen presenting cells for production of cell therapy products and immune monitoring studies 3. Cell therapy product manufacturing, including dendritic and tumor cell-based gene-modified and un- modified vaccines and purification and/or expansion of T lymphocytes (T regulatory cells, tumor infiltrating lymphocytes, tumor antigen-associated T cells, chimeric antigen receptor T cells) 4. An analytic laboratory that performs the dual functions of product quality testing and post-treatment immune monitoring During the project period, the CTC supported 19 cancer center investigators involved in 27 projects and 39 publications. In FY2015, the CTC supported 15 projects, of which 87% represented member projects and 55% of total usage supported peer-review-funded members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-19
Application #
9209814
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
19
Fiscal Year
2017
Total Cost
$103,046
Indirect Cost
$43,136
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
Research Institutes
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Padron, Eric; Ball, Markus C; Teer, Jamie K et al. (2018) Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood 131:2402-2405
Karolak, Aleksandra; Markov, Dmitry A; McCawley, Lisa J et al. (2018) Towards personalized computational oncology: from spatial models of tumour spheroids, to organoids, to tissues. J R Soc Interface 15:
Liu, Ying; Wang, Hua; Li, Qian et al. (2018) Radiologic Features of Small Pulmonary Nodules and Lung Cancer Risk in the National Lung Screening Trial: A Nested Case-Control Study. Radiology 286:298-306
Correa, John B; Brandon, Karen O; Meltzer, Lauren R et al. (2018) Electronic cigarette use among patients with cancer: Reasons for use, beliefs, and patient-provider communication. Psychooncology 27:1757-1764
Verduzco, Daniel; Kuenzi, Brent M; Kinose, Fumi et al. (2018) Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther 17:73-83
Lee, Morgan S; Tyson, Dinorah Martinez; Gonzalez, Brian D et al. (2018) Anxiety and depression in Spanish-speaking Latina cancer patients prior to starting chemotherapy. Psychooncology 27:333-338
de Mingo Pulido, Álvaro; Gardner, Alycia; Hiebler, Shandi et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. Cancer Cell 33:60-74.e6
Divakaran, Anand; Talluri, Siva K; Ayoub, Alex M et al. (2018) Molecular Basis for the N-Terminal Bromodomain-and-Extra-Terminal-Family Selectivity of a Dual Kinase-Bromodomain Inhibitor. J Med Chem 61:9316-9334
McIntyre, Jessica; Jiménez, Julio; Rivera, Yonaira M et al. (2018) Comparison of Health Communication Channels for Reaching Hispanics About Biobanking: a Pilot Trial. J Cancer Educ 33:833-841
Li, Gongbo; Boucher, Justin C; Kotani, Hiroshi et al. (2018) 4-1BB enhancement of CAR T function requires NF-?B and TRAFs. JCI Insight 3:

Showing the most recent 10 out of 1254 publications